ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 184

An Epigenome-Guided Approach to Causal Variant Discovery in Autoimmune Disease

Richard C. Pelikan1, Jennifer A. Kelly2, Yao Fu2, Caleb Lareau3, Graham B. Wiley1, Stuart Glenn1, Martin Aryee3,4, Courtney Montgomery5 and Patrick Gaffney2, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Department of Biostatistics, Harvard T.H. Chan School of Public Health, Charlestown, MA, 4Department of Pathology, Harvard Medical School, Boston, MA, 5Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmune diseases, Bioinformatics, Epigenetics, genomics and statistical methods

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Genome-wide association studies have identified thousands of genetic associations with complex human diseases and traits. However, establishing the truly causal regions of risk haplotypes is complicated by the correlation of many non-causal variants to genetic associations through linkage disequilibrium (LD). This has made translating genetic findings into functional mechanisms an inefficient, resource-intensive task.

Methods: Here, we expedite causal variant discovery for autoimmune diseases by identifying genetic variants (epiQTLs) that leave an epigenomic footprint of allelic imbalance in sequencing reads recovered by chromatin immunoprecipitation of enhancer marks (H3K4me1 and H3K27ac ChIP-seq). We aligned sequencing reads using the WASP pipeline to control for reference genome bias. We used the combined haplotype test (CHT) to statistically test for robust footprints of allelic imbalance. We also characterized the three-dimensional chromatin interaction topography among H3K27ac-marked active enhancers of our cell lines by HiChIP.

Results: We discovered a total of 6261 epiQTLs across 25 patient-derived EBV-transformed B-cell lines. We overlaid these epiQTLs onto risk haplotypes from 21 autoimmune (AI) diseases and found that 145 reported AI risk haplotypes contained one or more of our epiQTLs. A total of 14 epiQTL SNPs matched AI risk SNPs reported in the NHGRI GWAS catalog, while 180 epiQTLs were proxies of these reported SNPs. We found that epiQTLs located on disease risk haplotypes disproportionately influence gene expression variance, beyond what can be expected by random chance, over non-epiQTL variants in tight linkage disequilibrium. A majority (78%) of epiQTLs were located in chromatin loop anchors. Using a generalized linear model, we identified 571 epiQTLs – not associated with autoimmune disease – that modify gene expression from 68 previously established AI disease risk haplotypes through chromatin looping at FDR ≤5%. Expanding this analysis to include both risk haplotypes and independent eQTLs increased the number of epiQTLs with significant (FDR ≤ 5%) modifier effects on gene expression to 1062. Of these gene expression modifying interactions, 717 (68%) increased eQTL-driven gene expression by the epiQTL, while 345 (32%) suppressed eQTL-driven gene expression.

Conclusion: Our data suggest that the epiQTL approach can facilitate the decomposition of risk haplotypes into specific regions that are highly likely to contain functional causal variants. Moreover, epiQTLs not associated with disease haplotypes function to modify gene expression from risk haplotypes and eQTLs through long-range allele-dependent epigenetic mechanisms.


Disclosure: R. C. Pelikan, None; J. A. Kelly, None; Y. Fu, None; C. Lareau, None; G. B. Wiley, None; S. Glenn, None; M. Aryee, None; C. Montgomery, None; P. Gaffney, None.

To cite this abstract in AMA style:

Pelikan RC, Kelly JA, Fu Y, Lareau C, Wiley GB, Glenn S, Aryee M, Montgomery C, Gaffney P. An Epigenome-Guided Approach to Causal Variant Discovery in Autoimmune Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/an-epigenome-guided-approach-to-causal-variant-discovery-in-autoimmune-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-epigenome-guided-approach-to-causal-variant-discovery-in-autoimmune-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology